Verkazia® is the first and only topical immunomodulator approved for the treatment of vernal keratoconjunctivitis (VKC) for children and adults.1 VKC is a rare ocular condition that mainly affects children and adolescents.2,3 Unlike seasonal ocular conjunctivitis, VKC causes severe ocular surface inflammation that may lead to vision loss.2
Verkazia is a prescription-only eye drop containing 0.1% cyclosporine—a molecule shown to be effective in the management of VKC.1,4 It is uniquely formulated as a cationic ophthalmic emulsion, which improves corneal bioavailability of cyclosporine.1,5 Verkazia works by inhibiting T-cell activation along with reducing the level of immune cells and mediators that cause the chronic, severe, and potentially debilitating allergic ocular surface inflammation in those affected by VKC.1,2,4